Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury?

Old Drugs, New Concerns

A Unifying Ontology to Integrate Histological and Clinical Observations for Drug-Induced Liver Injury

NLA Task Force on Statin Safety--2014 update.

Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology

Novel Therapies, High-Risk Pediatric Research, and the Prospect of Benefit: Learning from the Ethical Disagreements

Gene Therapy Strategies to Restore ER Proteostasis in Disease.

Drug-Induced Liver Injury, Dosage, and Drug Disposition: Is Idiosyncrasy Really Unpredictable?

Radiation and Chest CT Scans: Are There Problems? What Should We Do?

“Black box” 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk

Direct-acting antivirals trump interferon-alpha in their capacity to rescue exhausted T cells upon HCV clearance

Living under a cloud: Electronic cigarettes and the dental patient

Oral bisphosphonate use in the elderly is not associated with acute kidney injury

Hepatitis C virus resistance to protease inhibitors

Newer monoclonal antibodies for hematological malignancies

Host-targeting agents for prevention and treatment of chronic hepatitis C – Perspectives and challenges